TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing an allo-SCT~* No history of celiac disease or non-celiac gluten sensitivity~* Male and female and all ethnic groups are eligible~Exclusion Criteria:~* Pregnant women~* Children are not eligible as the transplant program is certified as an adult only transplant program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prevention (gluten free diet) (Type: EXPERIMENTAL): Patients undergo a gluten free diet for 30 days during initial hospitalization for allo-SCT, from the time of admission to discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Microwave Ablation for Uterine Fibroids

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic fibroids with or without focal adenomyoma~2. Female gender~3. Age between 30 and 50~4. Pre or peri menopausal with FSH less than 40 mIU/ml~5. Negative urine pregnancy test~6. Uterine size less than 22 weeks based on physical exam assessment~7. Dominant intramural fibroid greater than or equal to 3 cm and less than or equal to 10 cm on imaging.~8. Good health other than history of leiomyomas. Chronic medications may be acceptable at the discretion of the research team.~9. Are using abstinence, mechanical (condoms, diaphragms) or sterilization methods of contraception and are willing to continue using them throughout the study.~10. Willing and able to give informed consent.~11. Willing and able to comply with study requirements.~12. Normal menstrual cycle with endometrial pathology excluded~Exclusion Criteria:~1. History of or current thromboembolic event (deep vein thrombosis, pulmonary embolus, stroke)~2. Other pelvic pathology as indicated by history or MR imaging such as endometriosis, ovarian tumor, acute or chronic pelvic inflammatory disease~3. Pregnant or Positive pregnancy test~4. Unexplained vaginal bleeding~5. Untreated severe cervical dysplasia~6. Abnormal adnexal /ovarian mass~7. Intrauterine device~8. Known recent rapid growth of fibroids, defined as a doubling in size in 6 months~9. Known bleeding tendency~10. Contraindication to MRI due to severe claustrophobia or implanted metallic device.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Microwave ablation (Type: OTHER): The uterine fibroid will be identified and located with ultrasonography. A microwave electrode appropriate for the size of target lesion is placed into the target lesion under ultrasound guidance. Appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: New Ischemic Cerebral Lesions After Endarterectomy vs. Stenting for the Treatment of Symptomatic Carotid Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria comprised:~* patient's age ≥ 18 years;~* 60-99% stenosis of the internal carotid artery (degree of stenosis assessed by means of Doppler sonography, CT angiography or catheter angiography);~* diameter of the target internal carotid artery not more than 7 mm;~* symptomatic lesion (a history of ipsilateral stroke, transient ischaemic attack or reversible ischaemic neurological deficit);~* localisation and morphology of the lesion making possible surgical eversion endarterectomy or endovascular angioplasty with stent implantation;~* written informed consent.~Exclusion criteria comprised:~* target lesion that has been previously stented;~* highly calcified lesions;~* very tortuous common and internal carotid arteries;~* occlusion of the contralateral carotid artery without adequate collateral circulation through the circle of Willis (revealed by means of transcranial Doppler sonography);~* anatomical contraindications for eversion endarterectomy;~* acute ipsilateral stroke;~* disabling stroke at any side;~* other severe pathologies of the brain resulting is significant loss of cerebral tissue and/or significant neurological deficits, such as extensive previous stroke or multiple lacunar infarcts;~* history of haemorrhagic transformation of ischaemic stroke;~* severe comorbidities (such as cancer or decompensated heart failure);~* allergy to aspirin, clopidogrel or ticlopidine;~* allergy to iodinated contrast media;~* pregnant women;~* women of reproductive age who do not use effective contraception;~* metallic implants (such as peacemakers and orthopaedic endoprostheses) or other known contraindications for magnetic resonance imaging;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carotid Artery Stenting (Type: ACTIVE_COMPARATOR): Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent with a proximal protection system Mo.Ma
- Endarterectomy carotid artery (Type: ACTIVE_COMPARATOR): Subjects will undergo carotid endarterectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 45 years and over who have been diagnosed with Parkinson's disease~* Subject signed informed consent~Exclusion Criteria:~* Gastroenterological diseases such as ulcerative colitis, Crohn's disease, celiac disease, gallbladder diseases (calculous cholecystitis, cholangitis, etc.) that are not related to functional disorders, a liver diseases or pancreas in medical history~* Exacerbations of chronic gastroenterological diseases~* Mental illness~* Oncology diseases~* Mental disorders~* Rheumatoid arthritis or other autoimmune diseases~* Acute infectious diseases or exacerbation of any diseases~* Recent (\<3 months) administration of proton pump inhibitors, antimicrobial therapy or surgical intervention~* Recent (\<3 weeks) use of probiotics, antacids, nonsteroidal anti-inflammatory drugs, laxatives~* Recent (\<14 days) administration of laxatives (excluding prucaloprid)~* Recent (\< 3 months) surgical intervention~* Pregnancy, planning to be pregnant or breast feeding at any point during the study or study enrollment~* Current alcohol/drug abuse (more than 3 points for women and 4 for men according to AUDIT-C questionnaire and/or more than 7 points on the AUDIT questionnaire) or addiction therapy within 12 months prior to screening~* Planned relocation from the home region during the study~* Stroke in medical history~* Any surgical intervention in the central nervous system~* Morbid obesity, BMI\> 35 kg / m2~* A medical history of carriage or disease associated with a history of human immunodeficiency viruses, hepatitis B, C or Treponema pallidum~* The patient's inability to understand the essence of the study and agree to participate in it. MoCA scores \<22~* 4-5 stage of the disease according to the Hen and Yara scale~* Severe somatic pathologies or any factors that, in the opinion of the doctor, may prevent the patient from being included in the study~* A medical history of serious head injuries~* Rheumatoid arthritis~* Tuberculosis

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Diagnosed Parkinson's disease (Type: None): Patients with incident Parkinson's disease
- Control (Type: None): Volunteers without diagnosed Parkinson's disease not meeting the exclusion criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically confirmed advanced (stage IIIB) or metastatic NSCLC.~* Subject had received one prior platinum-based chemotherapy and one prior PD-(L)1 inhibitor therapy for locally advanced or metastatic disease.~* Subject with ECOG performance status (PS) of 0 or 1.~* Subject with at least 1 evaluable (measurable or non-measurable) lesion by RECIST 1.1 in solid tumors criteria.~Key Exclusion Criteria:~* Subject who previously received docetaxel, canakinumab (or another IL-1β inhibitor), or any systemic therapy for their locally advanced or metastatic NSCLC other than one platinum-based chemotherapy and one prior PD-(L)1 inhibitor.~* Subject with EGFRor ALK positive tumor.~* History of severe hypersensitivity reaction to monoclonal antibodies, taxanes or excipients of docetaxel or canakinumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Safety run-in part: Canakinumab+docetaxel (Type: EXPERIMENTAL): Participants were treated with full doses of docetaxel 75mg/m\^2 intravenous and canakinumab 200 mg subcutaneous on Day 1 of each 21-Day cycle (dose level 1). Subjects were assessed for at least 2 complete cycles of treatment (21 days per cycle; a total of 42 days) for safety evaluation (DLT) to define RP3R. De-escalation to canakinumab 200 mg subcutaneous every 6 weeks + docetaxel 75 mg/m\^2, every 3 weeks could also be considered.
- Randomized part: Canakinumab + docetaxel (Type: EXPERIMENTAL): Participants were treated with canakinumab subcutaneous at RP3R and docetaxel at 75 mg/m\^2 every 3 weeks
- Randomized part: Placebo + docetaxel (Type: PLACEBO_COMPARATOR): Participants were treated with placebo subcutaneous at RP3R and docetaxel at 75 mg/m\^2 every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Staples Versus Suture for Cesarean Wound Closure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cesarean delivery~Exclusion Criteria:~* chronic use of immunosuppressive agents ( e.g.po steroids \> 2 weeks)~* significant immune compromising disease (e.g. AIDS, CD4\<200)~* contraindication to standard post operative pain management (acetaminophen, ibuprofen, oxycodone)~* refusal or inability to give consent

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Absorbable Subcuticular Surgical Suture (Type: ACTIVE_COMPARATOR): Patients in this arm will receive absorbable subcuticular suture for wound closure of cesarean deliveries.
- Surgical staples (Type: ACTIVE_COMPARATOR): Patients in this arm will receive surgical staples for wound closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with inflammatory bowel disease who on are stable doses of infliximab or adalimumab for at least 3 months who experience a secondary loss of response to the medication based on clinical symptoms.~* Presence of at least one objective marker of active disease: active disease based on endoscopy, elevated fecal calprotectin or serologic markers of inflammation (C-reactive protein or sedimentation rate).~* Crohn's patients have a Harvey Bradshaw index \>5~* Ulcerative colitis patients have a Ulcerative Colitis Clinical Score \> 5~* Have an undetectable or inadequate trough level of infliximab or adalimumab and detectable ATI or ADA.~* Oral corticosteroid therapy is allowed. (prednisone at a stable dose ≤30 mg/day, budesonide at a stable dose ≤9 mg/day, or equivalent steroid) provided that the dose has been stable for the 4 weeks immediately prior to enrollment if corticosteroids have recently been initiated~Exclusion Criteria:~* Previous noncompliant with medications~* \< 18 years of age or \>80 years of age.~* Congestive heart failure~* Abnormal liver tests alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2 × the upper limit of normal (ULN) or leucopenia WBC count \<3 × 109/L~* Pregnant or planning on becoming pregnant.~* Active tuberculosis or hepatitis B infection~* Any cancer within the past 5 years. (Exception non-melanomatous skin cancer.)~* Receiving any immunomodulator therapy within the past 3 months~* Evidence of or treatment for C. difficile infection within 60 days or other intestinal pathogen within 30 days prior to enrollment~* Clinically significant extra-intestinal infection (e.g., pneumonia, pyelonephritis) within 30 days of the initial screening visit~* Any live vaccinations within 30 days prior to study drug administration except for the influenza vaccine~* Any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus \[HIV\] infection, organ transplantation)~* Any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety~* Unable to give own informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Immunomodulator (Type: EXPERIMENTAL): Azathioprine, 6 mercaptopurine or methotrexate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Development of a Developmental Prognostic Tool for the Premature Child Based on Automated Spontaneous Motor Analysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Birth before 33 week of amenorrhea;~* Hospitalization in the Neonatal Department of the Saint-Étienne University Hospital~* Patient affiliated or entitled to a social security scheme;~* Authorization to shoot the holders of parental authority;~* Consent to participate in the study by the holders of parental authority~Exclusion Criteria:~* Need for ventilatory support;~* Difficulty of thermal regulation contraindicating the use of a heating cradle;~* Refusal of authorization to shoot by holders of parental authority;~* Refusal of participation in the study of holders of parental authority.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- premature child (Type: None): 300 premature child will be included. They will have three acquisitions during hospitalization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Skin infection of burn (whatever the surface, depth or location) supported by percutaneous administration of amikacin Age greater than 18 years Patient can be under guardianship or trusteeship Patient may present with cognitive impairment Patients receiving social coverage Patient who understood the objectives of the study, agreeing to participate in the study and who signed informed consent (or for which a trustee or guardian signed an informed consent if necessary) Patient mastering the French language~Exclusion Criteria:~minor patient or pregnant or lactating deprived of liberty patient Patient does not have insurance coverage Patient does not agreeing to participate in the study Patient allergic to amikacin or other antibiotic aminoglycosides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with Amikacin (Type: EXPERIMENTAL): Dressing impregnated by administration of amikacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 to 60 years of age~* Patients closely followed up for at least one year prior to inclusion (i.e. prior to the start of the baseline phase) if the diagnosis of the disease was made more than one year ago, to ensure that all possible episodes of clinical relapses which occurred during this interval of time were recorded and documented~* Multiple sclerosis that meets the 2010 revised McDonald criteria~* Relapsing/remitting type of multiple sclerosis (which includes clinically isolated syndromes if imaging shows brain lesions disseminated in space and time)~* Radiologically active disease defined by at least one gadolinium-enhancing lesion on a T1-weighted magnetic resonance imaging brain scan performed recently (i.e. within 3 months prior to inclusion)~* Disease-modifying drug naïve patients or patients with stable and adequately taken disease-modifying therapy (interferon β-1, glatiramer acetate, or dimethyl fumarate) for at least six months before inclusion (NOTE: Other disease modifying drugs might be added at a later date, depending on the results of current investigations)~* EDSS Score \<= 5.5~* Positive predictive test in vitro for patient's CD4+ cell reactivity to immunogenic peptide~* Women of childbearing age must have a negative pregnancy test and must use adequate contraception during the treatment and follow-up phase of the study (three pregnancy tests will be required prior to and during the study: (1) during the screening phase, (2) about one week prior to leukapheresis, and (3) about one week prior to re-infusion of autologous cells)~* Fully informed written consent obtained~Exclusion Criteria:~* Positive only for the HLA DRB1\*0101, DRB1\*0102, DRB1\*0401, DRB1\*0426 alleles or for the combination of the previous alleles.~* Evidence of clinical relapse and use of intravenous or oral corticosteroids within 30 days prior to inclusion~* Therapeutic escalation anticipated (including change of disease modifying drug), other than the cell-based immunotherapy of this study, within the next six months~* Significant coexisting systemic disease including renal insufficiency~* Positive serology for hepatitis B and C, AIDS and syphilis~* Participation in another interventional clinical study, currently or during the past three months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- IMP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Akershus University Hospital Retrospective Cohort Study of Family Based Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~• Clinical diagnosis of F50.0 Anorexia nervosa or F50.1 Atypical anorexia nervosa according to the International Classification of Diseases-10.~Exclusion Criteria:~• Patient was treated during the years 2018-2020 and FBT was never initiated according to patient health records.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 2015-2017 (Type: None): Patients treated for anorexia nervosa in the years 2015-2017 at Nedre Romerike outpatient clinic, Department of child and adolescent mental health services, Akershus university hospital.
- 2018-2020 (Type: None): Patients treated for anorexia nervosa in the years 2018-2020 at Nedre Romerike outpatient clinic, Department of child and adolescent mental health services, Akershus university hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial of a Bone Density Decision Aide

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* physicians involved in referring patients for DXA bone density testing~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 - Control (Type: None): Usual Bone Density Report
- 2 - Intervention (Type: None): Bone Density Report with Absolute 10-year Fracture Risk Decision Aide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues